Table 2.
Baseline comparison of subjects by treatment
| Clinical Measurement | Placebo (n=14) | Resveratrol (n=14) | p | ||
|---|---|---|---|---|---|
| Mean±SD | CI 95% | Mean±SD | CI 95% | ||
| Clamp M (mg/kg/min) | 4.3±0.9 | 3.8–4.8 | 4.4±1.3 | 3.7–5.2 | 0.705 |
| Insulin (mlU/L) | 14+/8 | 9–19 | 22±20 | 10–33 | 0.194 |
| HOMA (%) | 3.7±2.3 | 2.3–5.0 | 5.5±6.3 | 1.8–9.1 | 0.322 |
| 120 min data 2 h GTT (mg/dl) | 184±58 | 151–218 | 153±24 | 139–167 | 0.081 |
| AUC (mg/dl) | 345±77 | 301–389 | 310±41 | 286–333 | 0.145 |
| WBC (k/mcl) | 6.0±1.4 | 5.2–6.8 | 6.0±1.6 | 5.1–6.9 | 0.960 |
| CRP (mg/dl) | 0.33±0.17 | 0.24–0.43 | 0.58±0.34 | 0.39–0.78 | 0.734 |
| REE (k/cal/day) | 1778±204 | 1652–1898 | 1754±209 | 1627–1880 | 0.789 |
| BMI (kg/m2) | 33.8±3.3 | 32.0–35.7 | 35.0±3.0 | 33.2–36.7 | 0.317 |
| Age (years) | 47±8 | 42–52 | 48±9 | 43–60 | 0.772 |
Comparison of the baseline laboratory data, BMI and age of the total group of resveratrol and placebo treated subjects. Clamp M: mg/kg/min of dextrose required to maintain plasma glucose at level of 90–100 mg/dl during euglycemic hyperinsulinemic clamp; 120 min data: The blood glucose level at 120 min of a 2 h oral glucose tolerance test, GTT: Oral glucose tolerance test, AUC: Area under the curve, HOMA: Homeostatic model assessment, assesses insulin resistance and beta cell function, WBC: White blood cell count, CRP: C-reactive protein, TG: Serum triglycerides, REE: Resting energy expenditure, BMI: Body mass index, SD: Standard deviation, CI: Confidence interval.